IJCNP, Volume 3, Issue 10, 2025 ISSN: 2995-536X
https://medicaljournals.eu/index.php/IJCNP

INTERNATIONAL JOURNAL OF COGNITIVE NEUROSCIENCE AND PSYCHOLOGY

PEDIATRIC TIC DISORDERS: COMPREHENSIVE CLINICAL, GENETIC, AND IMMUNOLOGICAL CHARACTERIZATION FOR ENHANCED PROGNOSTICATION AND THERAPEUTIC STRATEGIES

Niyozov Sh. T.
MD, Associate Professor, Department of Neurology, Samarkand State Medical University

Akramova Z. A.
Independent Researcher Department of Neurology, Samarkand State Medical University

Ergashev S. S.
PhD Assistant, Department of Neurology, Samarkand State Medical University

Abstract: Over recent decades, the etiopathogenic view of tic disorders has shifted dramatically. Once interpreted mainly through psychological and behavioral frameworks, tics are now understood as multifactorial conditions with genetic, immunological, neurochemical, and environmental determinants. In children, tic disorders represent a heterogeneous set of neurodevelopmental syndromes characterized by recurrent, involuntary motor and/or vocal phenomena that may significantly disrupt academic performance, social functioning, and family life.

Key words: Tic disorders, Tourette syndrome, children, genetic markers, immunological abnormalities, PANDAS, autoimmunity, neurodevelopment, personalized medicine, prognosis, basal ganglia, streptococcal infection, molecular diagnostics, targeted therapy.

INTRODUCTION. Tic disorders comprise a spectrum of neurodevelopmental conditions marked by motor and/or vocal tics that can substantially impair the quality of life of affected children and their families. Contemporary estimates place pediatric prevalence between 0.4% and 3.8%, with Tourette syndrome occurring in approximately 0.3–0.9% of school-aged children. Over recent decades, the etiopathogenic view of tic disorders has shifted dramatically. Once interpreted mainly through psychological and behavioral frameworks, tics are now understood as multifactorial conditions with genetic, immunological, neurochemical, and environmental determinants. In children, tic disorders represent a heterogeneous set of neurodevelopmental syndromes characterized by recurrent, involuntary motor and/or vocal phenomena that may significantly disrupt academic performance, social functioning, and family life. Epidemiological studies report a pediatric prevalence of 0.4–3.8%, while Tourette syndrome affects up to 0.9% of schoolchildren. Although symptoms may appear “benign” or fluctuating in some patients, the overall burden is amplified by symptom severity and frequent comorbidity with ADHD, OCD, anxiety disorders, and autism spectrum disorders.

In the past twenty years, the field has moved from predominantly psychogenic explanations to a multifactorial model integrating inherited vulnerability, neurodevelopmental factors, immune and neuroinflammatory mechanisms, and environmental triggers. Family–twin and genome-wide studies support high heritability and a polygenic basis, implicating genes governing dopaminergic, serotonergic, and GABAergic neurotransmission, as well as synaptogenesis and neural plasticity. Concurrently, interest in immune-mediated pathways has grown, particularly the PANDAS/PANS framework, which posits that streptococcal and other triggers may, in some children, elicit cross-reactive autoimmune responses targeting basal ganglia and disrupting motor control networks.

Marked clinical heterogeneity—spanning age of onset, symptom phenomenology and dynamics, and comorbidity profiles—underscores the need for early risk stratification, prognostication, and

individualized treatment planning. Accordingly, integrating clinical data with immunologic and genetic biomarkers is gaining prominence for refined phenotyping, trajectory prediction, therapy selection, and treatment monitoring. Of special note are pharmacogenetic predictors of response to antipsychotic and neuromodulatory therapies, as well as indicators guiding immunomodulatory treatment in subgroups with evidence of immune involvement.

This review aims to synthesize current findings on the clinical, immunological, and genetic features of pediatric tic disorders, and to evaluate their prognostic relevance and practical implications for therapy optimization within a personalized medicine paradigm. The goal is to outline a coherent model linking biological mechanisms to clinical decision-making to improve both short- and long-term outcomes.

Genetics. Family studies demonstrate substantial heritability for Tourette syndrome ($h^2 = 0.25–0.77$), indicating a significant genetic contribution. Yet the genetic architecture—spanning rare and common variants—complicates the identification of specific markers readily applicable in clinical practice. Twin studies report concordance of 50–77% in monozygotic versus 8–23% in dizygotic pairs; first-degree relatives of Tourette patients carry a 10–100-fold higher risk than the general population. Candidate genes implicated include those in dopaminergic (DRD2, DRD4, DAT1, COMT), serotonergic (HTR2A, SLC6A4), and GABAergic (GABRA1, GABRB3) systems; polymorphisms in these pathways may alter basal ganglia neurotransmission, central to tic pathophysiology. Large-scale GWAS have identified risk loci such as CELSR3, MRPL3, and FLT3, highlighting roles for neurodevelopmental processes, synaptic plasticity, and immune regulation.

Immunology. The PANDAS hypothesis (Swedo et al.) proposes that, in genetically susceptible children, streptococcal antigens can molecularly mimic neuronal proteins of the basal ganglia, provoking cross-reactive autoantibodies and brain inflammation. Children with tics often show elevated antistreptococcal antibodies (antistreptolysin O, anti-DNase B) and antineuronal antibodies (e.g., to N-acetyl-β-D-glucosamine, tubulin, aldolase C). Increased proinflammatory cytokines (IL-17, TNF-α, IL-6) in serum and CSF further support a neuroinflammatory component. The broader PANS construct extends this model to diverse infectious and noninfectious triggers of autoimmune responses.

Clinical heterogeneity and prognosis. Considerable variability in presentation complicates course prediction. Subtyping by onset age, tic characteristics, comorbidities, and family history can refine prognostication. Earlier onset (before age 6), motor tics predominance, absent comorbidity, and positive family history generally predict more favorable outcomes. In contrast, later onset, prominent vocal tics, and co-occurring OCD and ADHD are linked to persistent symptoms.

Therapeutic implications. Insights into genetic and immune mechanisms support personalized treatment strategies. Pharmacogenetic variation in CYP2D6, COMT, and DRD2 may affect efficacy and tolerability of antipsychotics commonly used for tics. For children with immune-mediated features, immunomodulatory interventions—plasmapheresis, intravenous immunoglobulin, corticosteroids, and immunosuppressants—may be beneficial, though they require careful selection and safety monitoring.

Conclusions

- Multifactorial nature: Evidence supports a complex etiopathogenesis for pediatric tics, combining genetic predisposition, immune dysregulation, and environmental factors—necessitating comprehensive, multidisciplinary care.
- Genetic heterogeneity: Multiple genes affecting neurotransmission, neurodevelopment, and immune pathways contribute to risk; polymorphisms in dopaminergic, serotonergic, and GABAergic genes may inform therapeutic choices.
- Autoimmune mechanisms: A notable subset of children exhibits markers of autoimmunity (elevated antistreptococcal and antineuronal antibodies), aligning with PANDAS/PANS and supporting immunotherapy in selected cases.

- Prognostic integration: Combining clinical variables (onset age, tic profile, comorbidities) with genetic and immunologic indicators can enhance prediction of course and optimize treatment strategies.
- Personalized medicine: Pharmacogenetic insights enable more tailored pharmacotherapy, potentially improving effectiveness and minimizing adverse effects.
- Future research: Validation of genetic and immunologic biomarkers, standardized diagnostic/treatment pathways for tic subtypes, and long-term evaluations of personalized approaches remain priority areas.

REFERENCES

1. Augustin M., Groth C., Richter A., et al. Comprehensive genetic analysis of Tourette syndrome and related tic disorders reveals novel risk loci and shared genetic architecture. Nature Genetics. 2022;54:984–993.
2. Chang K., Frankovich J., Cooperstock M., et al. Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. Journal of Child and Adolescent Psychopharmacology. 2021;31(2):97–117.
3. Davis L.K., Yu D., Keenan C.L., et al. Partitioning the heritability of Tourette syndrome and obsessive–compulsive disorder reveals differences in genetic architecture. PLoS Genetics. 2020;16(6):e1008176.
4. Gromark C., Hesselmark E., Djupedal I.G., et al. Immunoglobulin and cytokine profiles in pediatric acute-onset neuropsychiatric syndrome: a systematic review and meta-analysis. Brain, Behavior, and Immunity. 2023;108:276–291.
5. Martino D., Ganos C., Pringsheim T.M. Tourette syndrome and chronic tic disorders: the clinical spectrum beyond tics. International Review of Neurobiology. 2021;143:1–33.
6. Murphy T.K., Brennan E.M., Johnco C., et al. Treatment of pediatric acute-onset neuropsychiatric disorder in a large survey population. Journal of Child and Adolescent Psychopharmacology. 2022;32(3):165–176.
7. Paschou P., Fernandez T.V., Sharp F., et al. Genetic architecture of Tourette syndrome: rare and common variants implicate immune and dopaminergic systems. Molecular Psychiatry. 2021;26:3239–3252.
8. Robertson M.M., Eapen V., Singer H.S., et al. Gilles de la Tourette syndrome. Nature Reviews Disease Primers. 2020;3:16097.